Top news of May: Supreme Court saves alirocumab; mobile phone use and BP; and more
Click Here to Manage Email Alerts
Healio and Cardiology Today have compiled the top cardiology headlines of May 2023.
Readers were most interested in a Supreme Court decision invalidating a pair of patents and allowing alirocumab to stay on the U.S. market; the link between irregular menstrual cycles and heart disease; a new indication for dapagliflozin; and more.
Supreme Court decision allows alirocumab to stay on US market
The U.S. Supreme Court unanimously ruled in favor of Regeneron and Sanofi that two of Amgen’s patents for PCSK9 inhibitor technology were invalid, allowing alirocumab to stay on the U.S. market. Read more
High weekly mobile phone use tied to high blood pressure risk
An analysis of UK Biobank data show people who reported high weekly mobile phone use to make or receive calls were more likely to develop hypertension during follow-up, with greater risk for those at genetic risk for hypertension. Read more
Short, long menstrual cycles may increase heart disease risk
Women with long or short menstrual cycles are more likely to develop CVD or atrial fibrillation compared with women reporting regular menstrual cycles, but they are no more likely to experience HF or stroke, researchers reported. Read more
Coronary artery calcium score, not polygenic risk score, best predicts heart disease risk
Data show CV risk discrimination improved when adding a coronary artery calcium score to a CHD prediction model based on traditional risk factors; however, there were no changes when adding a polygenic risk score. Read more
FDA expands dapagliflozin indication to include all patients with HF
The FDA expanded an indication for the SGLT2 inhibitor dapagliflozin to reduce risk for CV death, HF hospitalization and urgent HF visits for adults with HF across the full range of ejection fraction, according to an industry press release. Read more
Lipoprotein(a): The next frontier in CV risk reduction
This installment of Pipeline Pulse focuses on a single cardiovascular risk factor, lipoprotein(a), and examines two CV outcomes trials aimed at reducing CV events through Lp(a) reduction. Read more
AHA: Screening needed to assess common cognitive impairment after stroke
Cognitive impairment is common among stroke survivors and cognition screenings should be part of a person’s multidisciplinary follow-up care, according to a new scientific statement from the American Heart Association. Read more
Higher neuroticism level tied to incident AF, younger age at AF onset
People with a high level of neuroticism were more likely to develop atrial fibrillation, and to do so at a younger age, compared with people with lower levels, according to a study presented at Heart Rhythm 2023. Read more
Ambulatory vs. clinic blood pressure better predicts CV, all-cause death
Blood pressure measures obtained through ambulatory monitoring were more informative about risk for all-cause death or cardiovascular death than conventional clinic blood pressure readings, researchers reported. Read more
Most adults with FH do not reach guideline-recommended cholesterol targets
About 75% of adults with heterozygous familial hypercholesterolemia do not meet guideline-recommended LDL treatment targets, whereas women with familial hypercholesterolemia are less likely than men to be appropriately treated, data show. Read more
Collapse
Healio Coverage
Click Here to Manage Email Alerts